E6-RHDV-VLP-PADRE immunisation reduces tumour burden and increases survival in mice with pre-existing TC-1 tumours.

<p>(a) C57BL/6 mice (eight per group) were inoculated with 1×10⁵ TC-1 tumour cells/mouse s.c., vaccinated nine days later followed by a second vaccination after one week. Tumour area (b) and Kaplan-Meier survival curves (c) for mice vaccinated with E6-RHDV-VLP, RHDV-VLP or PBS. T cell proliferation and IFNγ secretion was measured following <i>in vitro</i> stimulation of splenocytes with PADRE from mice immunized with RHDV-VLP or RHDV-VLP-PADRE (d). Tumour area (e) and Kaplan-Meier survival curves (f) for mice vaccinated with E6-RHDV-VLP-PADRE, RHDV-VLP-PADRE or PBS immunized controls.